Physician profile
Rafael Villalobos-Nieto
NPI 1083638522
$7,683.10
in general payments reported to CMS, 2019-2025
30 companies · $2,126 in 2025
The $2,126 reported for 2025 was more than what 88% of Neurodevelopmental Disabilities (Pediatrics) providers received nationally (typical 2025 total: $136).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $996 · 2020: $507 · 2021: $612 · 2022: $817 · 2023: $1,227 · 2024: $1,399 · 2025: $2,126.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,751.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,751.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $1,868.40 | 2019-2025 | Qelbree, Qelbree, Oxtellar Xr |
| Ucb, INC. | $1,336.43 | 2019-2025 | Briviact, Fintepla, Nayzilam |
| Corium, LLC | $626.04 | 2023-2025 | Azstarys |
| Jazz Pharmaceuticals INC. | $552.56 | 2023-2025 | |
| Sunovion Pharmaceuticals INC. | $300.48 | 2019-2022 | |
| Acadia Pharmaceuticals INC | $260.03 | 2023-2025 | Daybue |
| Sarepta Therapeutics, INC. | $254.45 | 2019-2025 | Elevidys |
| Collegium Pharmaceutical, INC. | $244.93 | 2025 | Jornay Pm |
| Otter Pharmaceuticals, LLC | $237.10 | 2025 | Sympazan |
| Sk Life Science, INC. | $232.17 | 2022-2025 | |
| Ptc Therapeutics, INC. | $224.68 | 2021-2025 | Emflaza |
| Catalyst Pharmaceuticals, INC. | $209.55 | 2023-2025 | Fycompa |
| Takeda Pharmaceuticals U.S.A., INC. | $200.43 | 2021-2024 | Elaprase |
| Upsher-Smith Laboratories LLC | $188.22 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $185.26 | 2023-2024 | Aptiom |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $119.55 | 2019 | |
| Livanova USA, INC. | $96.48 | 2023-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Azurity Pharmaceuticals, INC. | $92.24 | 2022-2024 | Eprontia, Zonisade |
| Greenwich Biosciences, INC. | $68.96 | 2019-2021 | |
| Biocodex, INC. | $61.72 | 2023-2025 | Diacomit |
| Springworks Therapeutics, INC. | $60.00 | 2025 | Gomekli |
| Shire North American Group INC | $53.56 | 2019 | |
| Cycle Pharmaceuticals INC | $39.77 | 2025 | Tascenso Odt |
| Itf Therapeutics LLC | $39.75 | 2024-2025 | |
| Pyros Pharmaceuticals, INC. | $30.36 | 2024 | Vigpoder |
| Inspire Medical Systems, INC. | $25.59 | 2025 | Inspire |
| Immedica Pharma US, INC. | $24.07 | 2024 | |
| Tris Pharma INC | $19.37 | 2019 | |
| Ironshore Pharmaceuticals INC. | $18.35 | 2019 | |
| Zogenix INC. | $12.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rafael Villalobos-Nieto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.